BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 29728519)

  • 1. Characterization of 3 Novel Tau Radiopharmaceuticals,
    Wong DF; Comley RA; Kuwabara H; Rosenberg PB; Resnick SM; Ostrowitzki S; Vozzi C; Boess F; Oh E; Lyketsos CG; Honer M; Gobbi L; Klein G; George N; Gapasin L; Kitzmiller K; Roberts J; Sevigny J; Nandi A; Brasic J; Mishra C; Thambisetty M; Mogekar A; Mathur A; Albert M; Dannals RF; Borroni E
    J Nucl Med; 2018 Dec; 59(12):1869-1876. PubMed ID: 29728519
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of
    Kuwabara H; Comley RA; Borroni E; Honer M; Kitmiller K; Roberts J; Gapasin L; Mathur A; Klein G; Wong DF
    J Nucl Med; 2018 Dec; 59(12):1877-1884. PubMed ID: 30097505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of
    Honer M; Gobbi L; Knust H; Kuwabara H; Muri D; Koerner M; Valentine H; Dannals RF; Wong DF; Borroni E
    J Nucl Med; 2018 Apr; 59(4):675-681. PubMed ID: 28970331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of
    Bullich S; Barret O; Constantinescu C; Sandiego C; Mueller A; Berndt M; Papin C; Perrotin A; Koglin N; Kroth H; Pfeifer A; Tamagnan G; Madonia J; Seibyl JP; Marek K; De Santi S; Dinkelborg LM; Stephens AW
    J Nucl Med; 2020 Jun; 61(6):920-927. PubMed ID: 31712324
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic Evaluation of the Tau PET Radiotracer
    Wooten DW; Guehl NJ; Verwer EE; Shoup TM; Yokell DL; Zubcevik N; Vasdev N; Zafonte RD; Johnson KA; El Fakhri G; Normandin MD
    J Nucl Med; 2017 Mar; 58(3):484-491. PubMed ID: 27660144
    [No Abstract]   [Full Text] [Related]  

  • 6. Kinetic Modeling of the Tau PET Tracer
    Barret O; Alagille D; Sanabria S; Comley RA; Weimer RM; Borroni E; Mintun M; Seneca N; Papin C; Morley T; Marek K; Seibyl JP; Tamagnan GD; Jennings D
    J Nucl Med; 2017 Jul; 58(7):1124-1131. PubMed ID: 27908967
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with
    Lohith TG; Bennacef I; Vandenberghe R; Vandenbulcke M; Salinas CA; Declercq R; Reynders T; Telan-Choing NF; Riffel K; Celen S; Serdons K; Bormans G; Tsai K; Walji A; Hostetler ED; Evelhoch JL; Van Laere K; Forman M; Stoch A; Sur C; Struyk A
    J Nucl Med; 2019 Jan; 60(1):107-114. PubMed ID: 29880509
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [
    Guehl NJ; Wooten DW; Yokell DL; Moon SH; Dhaynaut M; Katz S; Moody KA; Gharagouzloo C; Kas A; Johnson KA; El Fakhri G; Normandin MD
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2099-2111. PubMed ID: 31332496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of [
    Schmidt ME; Janssens L; Moechars D; Rombouts FJR; Timmers M; Barret O; Constantinescu CC; Madonia J; Russell DS; Sandiego CM; Kolb H
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3176-3185. PubMed ID: 32535652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau PET imaging with
    Mueller A; Bullich S; Barret O; Madonia J; Berndt M; Papin C; Perrotin A; Koglin N; Kroth H; Pfeifer A; Tamagnan G; Seibyl JP; Marek K; De Santi S; Dinkelborg LM; Stephens AW
    J Nucl Med; 2020 Jun; 61(6):911-919. PubMed ID: 31712323
    [No Abstract]   [Full Text] [Related]  

  • 11. [
    Sanabria Bohórquez S; Marik J; Ogasawara A; Tinianow JN; Gill HS; Barret O; Tamagnan G; Alagille D; Ayalon G; Manser P; Bengtsson T; Ward M; Williams SP; Kerchner GA; Seibyl JP; Marek K; Weimer RM
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2077-2089. PubMed ID: 31254035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand
    Betthauser TJ; Cody KA; Zammit MD; Murali D; Converse AK; Barnhart TE; Stone CK; Rowley HA; Johnson SC; Christian BT
    J Nucl Med; 2019 Jan; 60(1):93-99. PubMed ID: 29777006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Comparison of Tau Radioligands
    Betthauser TJ; Lao PJ; Murali D; Barnhart TE; Furumoto S; Okamura N; Stone CK; Johnson SC; Christian BT
    J Nucl Med; 2017 Jun; 58(6):996-1002. PubMed ID: 27856627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [
    de Vries BM; Timmers T; Wolters EE; Ossenkoppele R; Verfaillie SCJ; Schuit RC; Scheltens P; van der Flier WM; Windhorst AD; van Berckel BNM; Boellaard R; Golla SSV
    Mol Imaging Biol; 2021 Aug; 23(4):550-559. PubMed ID: 33443720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351.
    Oh M; Oh SJ; Lee SJ; Oh JS; Roh JH; Chung SJ; Lee JH; Lee CS; Kim JS
    Clin Nucl Med; 2020 Nov; 45(11):841-847. PubMed ID: 32910050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.
    Baker SL; Lockhart SN; Price JC; He M; Huesman RH; Schonhaut D; Faria J; Rabinovici G; Jagust WJ
    J Nucl Med; 2017 Feb; 58(2):332-338. PubMed ID: 27587706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
    Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
    J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.
    Jonasson M; Wall A; Chiotis K; Saint-Aubert L; Wilking H; Sprycha M; Borg B; Thibblin A; Eriksson J; Sörensen J; Antoni G; Nordberg A; Lubberink M
    J Nucl Med; 2016 Apr; 57(4):574-81. PubMed ID: 26795290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.
    Shcherbinin S; Schwarz AJ; Joshi A; Navitsky M; Flitter M; Shankle WR; Devous MD; Mintun MA
    J Nucl Med; 2016 Oct; 57(10):1535-1542. PubMed ID: 27151986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
    Okamura N; Furumoto S; Harada R; Tago T; Yoshikawa T; Fodero-Tavoletti M; Mulligan RS; Villemagne VL; Akatsu H; Yamamoto T; Arai H; Iwata R; Yanai K; Kudo Y
    J Nucl Med; 2013 Aug; 54(8):1420-7. PubMed ID: 23857514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.